• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245331 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
! {8 P7 O8 o+ W4 E% Y6 J& V9 UNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ; V# e# |" N& [
+ Author Affiliations- e/ ^0 O2 H) x3 L4 V- c

5 d" p( J3 f1 {9 F5 D. N1 o1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . w: D% F& L& i: i* f3 F  b* B9 S$ C9 `
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 g2 o. ]  l5 {9 Q' L  C
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 B% e6 h; R) E) o2 ~4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
4 e0 b5 t3 V5 a: ]5 Q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 2 l5 Q0 ~6 n* h# {+ E
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
! G1 m# P9 n* t) {' c9 y7Kinki University School of Medicine, Osaka 589-8511, Japan 2 _. e: }# J* ?( {9 w
8Izumi Municipal Hospital, Osaka 594-0071, Japan
5 T5 a. D$ t) U& {: h! M1 a6 q# k9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 u" M4 }, [' O$ W* H
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
, }/ _( \2 g% B0 t+ gAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 5 s! o" a5 z* }. Z
" w6 ~, f. v" v, J) A0 f  i
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 9 y8 Z  B+ M0 u; c7 p, p6 P

" D3 l8 K1 M% s# n* iAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
* r; ]4 e4 V8 b5 e( y; ]& _: f4 P! a; f: A0 }
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  1 T: X8 I$ N6 u8 K. B' r& D) v

! c, J% R4 X% X, y' {' C2 A' m0 ~Published online on: Thursday, December 1, 2011
: N* l3 Y4 y" \3 [" x8 V
+ ]3 _" Y! z  ]8 GDoi: 10.3892/ol.2011.507 , [' Y9 w/ P7 E0 L2 _

% m* n, y3 A- k3 E; K/ QPages: 405-410 + L- s) R! r0 O
& O; R6 G8 P, }" `
Abstract:/ ]% U* X5 {  X# [# f: G
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.. c! y8 V  p4 y- ~9 W& Z: r# m$ h
) h) H4 ^( D' {+ }1 i  Y1 L
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population9 v8 }& g: y* O% M
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
( Y# J! {0 Z1 g8 V+ Author Affiliations
: E! Z" z- Q3 p5 p: E9 k0 m1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 7 @, l" H0 G3 ~- E' ?
2Department of Thoracic Surgery, Kyoto University, Kyoto " T' ]  ~8 G% e& T( P# p
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 1 f0 \- X" a$ K6 o& }2 y4 D
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp . E2 H8 K. O. R0 L& G
Received September 3, 2010.
4 }% E9 a, s9 w* pRevision received November 11, 2010. 2 D% M1 z6 A0 r3 l
Accepted November 17, 2010. 7 Q! f0 U4 ^0 s$ e( E7 x
Abstract
1 V$ K. Q3 u- i3 b+ ZBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 2 L* M1 ]4 ?0 P' S6 H
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 1 F/ l$ E, d1 X: e" R# Z# Q$ _( ?
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. % t  L# ]4 M1 W- W/ x2 V" ?8 u, d
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
9 B& B5 }6 M) {/ w) D' ]2 H8 b3 P' r
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。$ G' D; T+ C0 ]( k3 s  B* N! G
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?/ n$ ^! z0 j' Y. o# A- P
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
" q1 L6 ~5 z1 `7 E$ Mhttp://clinicaltrials.gov/ct2/show/NCT01523587
# F0 u( B/ F8 d4 z+ e: ~% t7 A! H2 S& g5 M, {( e4 `: J5 `
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC) q# V  D$ y# U" b7 a* ~8 J
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
% I  L: v2 h/ l% |7 G
8 X9 C! x% j( ]  _6 u从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。8 L( V' v) S0 _& a+ ]0 p. K3 S
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
  Y( c7 ~2 W: U1 Z( y5 j7 q5 ~% N5 ~从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。( X8 H4 s( l. P* `9 h
至今为止,未出 ...
- k* D  d8 R; Q% p' P
没有副作用是第一追求,效果显著是第二追求。  J6 P6 Y: W$ w. J( [) _7 C  R
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表